Parkinson’s Disease – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Parkinson’s Disease Emerging Therapy and TPP Insights

Thelansis’s “Parkinson’s Disease Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Parkinson’s Disease Overview

Parkinson’s Disease (PD) is recognized as a complex, chronic, and progressive multisystem neurodegenerative disorder, not solely a motor system disorder, resulting from the progressive loss of dopamine-producing neurons in the substantia nigra pars compacta and the accumulation of misfolded alpha-synuclein protein into Lewy bodies, which also spread to other brain regions and the peripheral nervous system years before diagnosis. The classic motor features required for clinical diagnosis according to the Movement Disorder Society (MDS) criteria include bradykinesia (slowness of movement) along with at least one of the following: resting tremor (often “pill-rolling”), or rigidity (stiffness), with postural instability typically manifesting in later stages. Crucially, the up-to-date understanding emphasizes the significant and often disabling non-motor symptoms that can predate motor onset by years—such as olfactory dysfunction (loss of smell), REM sleep behavior disorder (acting out dreams), constipation, and mood disorders like depression and anxiety—all reflecting disturbances in non-dopaminergic systems that are now integral to the contemporary diagnostic and treatment paradigm.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)